Untitled-2 Untitled-2 Untitled-2
Accelerating
Healthcare Innovation
1315 Capital invests in exceptional healthcare teams and companies

1315 Capital is a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare service companies. We target markets where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.

Investment
Leadership

The 1315 Capital investment team combines financial and business development expertise with deep industry knowledge to support the growth of our portfolio companies.

Learn More

OPERATING
TEAMS

1315 Capital employs a unique Operating Team model to navigate diligence, drive decisions, and achieve premium exits.

Learn More

Tangible
ENGAGEMENT

1315 Capital has a deep network that it leverages for management talent, advisors, deal sourcing, diligence, and boards roles.

Learn More

News & Events
FDA OK’s Innovative Health to reprocess SJM’s ViewFlex Xtra ultrasound catheter
May 18, 2018
Encore Dermatology Inc. Announces the Launch of IMPOYZ (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid
May 01, 2018
Stockholders Approve Genoptix Acquisition of Rosetta Genomics
April 26, 2018
Portfolio

Special needs equipment and supply company that serves the pediatric and adult special needs population.

Cosmeceutical company providing natural, mineral-based approach to skin protection and skin health.

Dermatology company committed to delivering innovative prescription therapies and medical devices to dermatologists.

Oncology diagnostics company that provides oncologists and pathologists with comprehensive testing solutions in hematology and solid tumor molecular profiling.

Cost-containment service company focused on reprocessing single-use medical devices.

Specialty pharmaceutical company focused on nutraceutical and women’s health products.

Medical device company focused on the orthopedic oncology market.

Medical technology company providing advanced wound care products to patients with chronic wounds.

Generic Levitra - active ingredient: Vardenafil. Presented at dosages of 20, 40 mg, and compatible with the alcohol version. The effect occurs after an average of 30-40 minutes after administration. Read more: